Serum KL-6 has been reported to represent a sensitive biomarker for interstitial lung diseases (ILDs) [18-20], but presumably KL-6 can be detectable also in airway secretions especially in disorders associated with mucus production such as COPD. Here, MUC1 is linked to interstitial lung disease.